Sipatrigine

Drug Profile

Sipatrigine

Alternative Names: 619C89; B 619C; BW 619C89

Latest Information Update: 24 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-ischaemics
  • Mechanism of Action Calcium channel antagonists; Glutamate-antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cerebral ischaemia; Stroke

Most Recent Events

  • 30 Oct 2001 Suspended - Phase-II for Cerebral ischaemia in United Kingdom (unspecified route)
  • 30 Oct 2001 Suspended - Phase-II for Stroke in France (unspecified route)
  • 30 Oct 2001 Suspended - Phase-II for Stroke in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top